High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer

Overview

Journal Thyroid

Date 2020 May 23

PMID 32438862

Citations 12

Authors

Min Ji Jeon

Mi-Hyeon You

Ji Min Han

Soyoung Sim

Hyun Ju Yoo

Woo Kyung Lee

Tae Yong Kim

Dong Eun Song

Young Kee Shong

Won Gu Kim

Won Bae Kim

Affiliations

Soon will be listed here.

Abstract

We examined the changes in glucose metabolites of papillary thyroid cancer (PTC) and identified phosphoglycerate dehydrogenase (PHGDH) as a potential target. The role of in the proliferation and tumorigenesis of thyroid cancer cells and its clinical significance were analyzed. Glucose metabolites of various thyroid tissues were analyzed via targeted metabolomics analysis. experiments using s, inhibitor (NCT503), or overexpression in thyroid cell lines (BCPAP, 8505C, and Nthy-Ori) were performed. experiments were performed by using . Human tissue samples and The Cancer Genome Atlas (TCGA) data were used to validate the experimental findings. knockdown in BCPAP and 8505c cell lines significantly inhibited cell viability, colony formation, and tumor spheroid formation compared with the control. In addition, treatment with NCT503 showed similar results. inhibition by both knockdown and treatment with NCT503 significantly inhibited the expression of embryonic cancer stemness markers (, , , and ). overexpression in Nthy-Ori cells significantly increased cell viability and colony formation. The stemness markers were significantly increased after overexpression. knockdown significantly inhibited tumor growth in an mouse xenograft study using 8505c cells. The protein expression of Oct4 in tumors was significantly reduced after knockdown. The associations between expression and stemness markers were confirmed in the TCGA data and human thyroid tissue samples. Positive PHGDH protein expression was associated with metastases of PTC. expression is induced in thyroid cancer and is associated with stemness and aggressiveness of PTC.

Citing Articles

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.

PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.

Crosstalk between thyroid CSCs and immune cells: basic principles and clinical implications.

Li X, Han H, Yang K, Li S, Ma L, Yang Z Front Immunol. 2025; 15():1476427.

PMID: 39776907 PMC: 11703838. DOI: 10.3389/fimmu.2024.1476427.

PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.

Jasani N, Xu X, Posorske B, Kim Y, Wang K, Vera O Cancer Res. 2024; 85(2):314-328.

PMID: 39495254 PMC: 11735329. DOI: 10.1158/0008-5472.CAN-24-2471.

Molecular glue triggers degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH.

Huang Z, Zhang K, Jiang Y, Wang M, Li M, Guo Y Acta Pharm Sin B. 2024; 14(9):4001-4013.

PMID: 39309493 PMC: 11413658. DOI: 10.1016/j.apsb.2024.06.001.

PHGDH: a novel therapeutic target in cancer.

Lee C, Hwang Y, Kim M, Park Y, Kim H, Fang S Exp Mol Med. 2024; 56(7):1513-1522.

PMID: 38945960 PMC: 11297271. DOI: 10.1038/s12276-024-01268-1.

References

Zhang B, Zheng A, Hydbring P, Ambroise G, Ouchida A, Goiny M . PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis. Cell Rep. 2017; 19(11):2289-2303. DOI: 10.1016/j.celrep.2017.05.067. View

Lee C, Yu C, Wang B, Chang W . Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2015; 7(2):1215-26. PMC: 4811455. DOI: 10.18632/oncotarget.6261. View

Mullarky E, Mattaini K, Vander Heiden M, Cantley L, Locasale J . PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell Melanoma Res. 2011; 24(6):1112-5. DOI: 10.1111/j.1755-148X.2011.00919.x. View

Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J . Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006; 66(22):10795-804. DOI: 10.1158/0008-5472.CAN-06-0755. View

Johnson S, Chen H, Lo P . Tumorsphere Formation Assays. Bio Protoc. 2016; 3(3). PMC: 4972326. DOI: 10.21769/bioprotoc.325. View

Coelho R, Fortunato R, Carvalho D . Metabolic Reprogramming in Thyroid Carcinoma. Front Oncol. 2018; 8:82. PMC: 5876306. DOI: 10.3389/fonc.2018.00082. View

Balla M, Yadav H, Pandey B . Tumorsphere assay provides a better in vitro method for cancer stem-like cells enrichment in A549 lung adenocarcinoma cells. Tissue Cell. 2019; 60:21-24. DOI: 10.1016/j.tice.2019.07.003. View

Samanta D, Park Y, Andrabi S, Shelton L, Gilkes D, Semenza G . RETRACTED: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. Cancer Res. 2016; 76(15):4430-42. DOI: 10.1158/0008-5472.CAN-16-0530. View

Kroemer G, Pouyssegur J . Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13(6):472-82. DOI: 10.1016/j.ccr.2008.05.005. View

10.

Possemato R, Marks K, Shaul Y, Pacold M, Kim D, Birsoy K . Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011; 476(7360):346-50. PMC: 3353325. DOI: 10.1038/nature10350. View

11.

Malta T, Sokolov A, Gentles A, Burzykowski T, Poisson L, Weinstein J . Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018; 173(2):338-354.e15. PMC: 5902191. DOI: 10.1016/j.cell.2018.03.034. View

12.

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

13.

Sun W, Kim H, Jung W, Koo J . Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. J Transl Med. 2016; 14(1):168. PMC: 4898323. DOI: 10.1186/s12967-016-0915-8. View

14.

You M, Jeon M, Kim T, Kim W, Shong Y, Kim W . Expression of Modulates the Progression of Mutated Thyroid Cancer Cells. Endocrinol Metab (Seoul). 2019; 34(2):203-212. PMC: 6599905. DOI: 10.3803/EnM.2019.34.2.203. View

15.

Sung T, Kim M, Kim T, Kim W, Park Y, Song D . Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma. Thyroid. 2015; 25(9):1020-5. DOI: 10.1089/thy.2015.0079. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

FEINE U, Lietzenmayer R, Hanke J, Held J, Wohrle H, Muller-Schauenburg W . Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996; 37(9):1468-72. View

18.

Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T . Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008; 7:72. PMC: 2569965. DOI: 10.1186/1476-4598-7-72. View

19.

Pacold M, Brimacombe K, Chan S, Rohde J, Lewis C, Swier L . A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol. 2016; 12(6):452-8. PMC: 4871733. DOI: 10.1038/nchembio.2070. View

20.

Sharif T, Martell E, Dai C, Ghassemi-Rad M, Lee K, Singh S . Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. Cell Death Dis. 2018; 9(10):990. PMC: 6155240. DOI: 10.1038/s41419-018-0997-8. View